Skip to main content
. 2006 Feb 16;573(Pt 1):199–210. doi: 10.1113/jphysiol.2006.106013

Figure 3. FAT/CD36 protein in resting (A) and chronically contracting muscles (B) treated with the PPARα activator Wy 14,643 and the PPARγ activator rosiglitazone.

Figure 3

Data are means ± s.e.m. n = 4 – 5 muscles for each group at each data point. *P < 0.05, chronic contraction versus day 0. **P < 0.05, chronic contraction + rosiglitazone versus day 0. ***P < 0.05, chronic contraction + Wy 14,643 versus day 0. †P < 0.05, chronic contraction + Wy 14,643 versus chronic contraction, and chronic contraction + Wy 14,643 versus chronic contraction + rosiglitazone.